Thu, Jul 10, 2014, 5:12 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

macugen_rules 83 posts  |  Last Activity: 3 hours ago Member since: Jul 18, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Achillion is inching closer to release Data for the Crossover studies with Sofosbuvir and Ach-3102. If the Data show 100% cure rate; it will prove once for all the company second generation NS5A is truly one of the best in class. Don't have to wait for long. A surge in pps is very possible and rightfully so.

    Sentiment: Hold

  • Reply to

    OT: Sidelurker

    by macugen_rules Jul 7, 2014 7:17 PM
    macugen_rules macugen_rules Jul 8, 2014 12:40 PM Flag

    One thing differentiates myself and others is I have been in this stock for many years when 1625 was still in its Infantile Stage. Being long, short or just trading the drought in any stock is the Norm in this Market. Where the Hatred comes from beat me?.
    I have never said nor gave an outlandish valuation ( the 40, 50 etc...). I don't know until there is a Deal in the making. Meantime, the science is there and I do believe this company is much better poised than it was 2 years ago when the former CEO with his Pitch 'Grin from ear to ear' while he cashed his million in options. The guy is worthless and still is these days.
    You do what you see fit. I am not selling until I see full valuation.

    Sentiment: Hold

  • macugen_rules by macugen_rules Jul 7, 2014 7:17 PM Flag

    First off I don't hate retail shorts. One thing I would want you to consider is the very near future of the crossover studies combining Solvadi and Ach-3102. The eight-week trial is completed, followed by 6-week duration therapy. Hedge Funds who shorted the stock are banking on the ability of Achillion to compete and catch up with the likes Gilead, Abbvie, Merck and BMS who got approval for their two DAAs regimen in Japan today for treating HepC-1b patients.
    I agreed Achillion is by far the underdog so was Idenix when those Hedge Funds were betting Huge they won't succeed....so 35% of Idenix float were shorted heavily. Look at the stiff penalties those people are paying now.
    Your gain in shorting ACHN is limited; your Losses could be exponential. Think about it!

    Sentiment: Hold

  • Reply to

    No strength to go higher than this level

    by sidelurker Jul 7, 2014 12:07 PM
    macugen_rules macugen_rules Jul 7, 2014 12:29 PM Flag

    ill advice to others dude!. You bet the farm last month and shorted 23k @6.89. You stated another 8k this morning @7.63. Your average up on your shorts stands @7.081 on 31k. What quick buck are you talking about??LOL. By day end, this stock will be back to the 7.50+ range. Watch it.

    Sentiment: Hold

  • Reply to

    Good Chance the Hold on Sovaprevir

    by macugen_rules Mar 15, 2014 1:34 PM
    macugen_rules macugen_rules Jul 1, 2014 9:48 PM Flag

    I will re-post this message for Finchfuller so just maybe his tolerance to daily fluctuation is more bearable.
    First sentence should read : The FDA could lift the Hold on 1625 in 2Q 2014....
    Unfortunately quite a few folks have thrown in the towel for many reasons ( Cut losses and moved on or forced to cut losses because they were on margins ). To tell you the Truth; it was also disheartening to me for those long months. If it wasn't for RA Capital's commitment to the stock, I would never have averaged my large holding down to 4 bucks. When my portfolio was in deep Red, I would spend a tremendous amount of my week-end time digging deeper into any available resources regarding this Company. Hope this Analogy helps!

  • Reply to

    Sound Familiar isn't it?

    by macugen_rules Jun 27, 2014 6:01 PM
    macugen_rules macugen_rules Jun 27, 2014 6:16 PM Flag

    Mr Luly,
    The one I am aware of was trial dubbed -007 where SVR12 showed 100% cure rate even for the patient who had all 6 baseline mutations. When you are a CEO of a Company; you really need to be fair and subjective about what you said; otherwise, you may make sound like an Jackarse!

  • macugen_rules by macugen_rules Jun 27, 2014 6:01 PM Flag

    This is what Jay Luly, Ceo of Enanta commented regarding recent acquisition of Idenix vis a vis Achillion:

    'But Luly provided Benzinga some insight. He began by noting that Achillion’s share price has been very depressed recently.

    “I think in part it is because they had a stretch of some not-so-good news," he said. "They went on clinical hold with one of their molecules, another one of their programs showed data that was not the strongest that people had hoped for, so their stock went way down.”

    What another of their programs???. Are you related to Adam Gefvert Mr. Luly?LOL.

    Sentiment: Hold

  • Reply to

    Dropping price

    by edgautr Jun 25, 2014 11:31 AM
    macugen_rules macugen_rules Jun 25, 2014 1:21 PM Flag

    Edgautr
    Then I need to remind you to spend some time listening to the JMP presentation now in archive. I hope to see you make more than a 'buck' by staying a few more months in ACHN.

  • Reply to

    Dropping price

    by edgautr Jun 25, 2014 11:31 AM
    macugen_rules macugen_rules Jun 25, 2014 12:42 PM Flag

    Typo: 3/31/2014 instead of 20140.

  • Reply to

    Dropping price

    by edgautr Jun 25, 2014 11:31 AM
    macugen_rules macugen_rules Jun 25, 2014 12:39 PM Flag

    mets1p/edgautr
    End of last quarter(3/31/20140) showed RA Capital Management LL held 3 million shares in CALL which they haven't filed, that's 30,000 contracts and @ what month and strike price?. I don't know because they haven't filed. But guessing by the timing of those calls they bought when the stock traded in the low 2; RA Capital is slated to return million of dollars if they sold those calls last Friday ( Double/Triple witching Day ).

  • Reply to

    Dropping price

    by edgautr Jun 25, 2014 11:31 AM
    macugen_rules macugen_rules Jun 25, 2014 12:15 PM Flag

    A lot of people also bought over 8 too. Clearly the 10 of millions shares traded didn't come from me and you. So far filings showed QVT and RA Capital were doing what any Funds or traders would do. Took some off the table, locked in profit and maybe reload down the road. Funds need to show a return to their own Investors. In the case of RA Capital and their partner Blackwell; buying shares in the low 2s and selling just a fraction in the 8s are a right thing to do.
    Going back to your question. How much Tolerance/Conviction do you have in Achillion?. Next is your Financial situation. Could you average down?. At one point to be exact on June 6th, my portfolio still showed a Huge Paper Loss and If I didn't average down when RA Capital jumped in; I would still be in the Red.
    Again I need to bring to your attention regarding those 10 of millions shares traded for the last 2 weeks.
    Towards the middle of August, I will know exactly who were selling, new buys or accumulating.

  • macugen_rules macugen_rules Jun 24, 2014 6:01 PM Flag

    LOL! there the Fuss about RA this time. Last time, shorts got complacent and shorted more based on QVT's 1.8 million shares sold. Again they want to spread FUD and make a big deal this without knowing the fact RA Capital bought the Majority about 19% of their Holding under 3 bucks. Funny about the shorts arguments. They think Institutions/Funds/Insiders aren't entitled to book profits......Only 'Them' can.
    Form 4 Filing (6/20/2014)
    Out of the 800,000 shares sold last Friday:
    The securities sold include 668,000 shares for RA Capital Healthcare Fund, L.P. (the "Fund") and 132,000 shares for an account owned by Blackwell Partners, LLC (the "Blackwell Account").
    Out of the other 80,000 shares:
    The securities sold include 66,800 shares for RA Capital Healthcare Fund, L.P. (the "Fund") and 13,200 shares for an account owned by Blackwell Partners, LLC (the "Blackwell Account").

    RA Capital 13G:
    Aggregate Amount Beneficially Owned by Each Reporting Person
    22,486,007 shares
    Percent of Class Represented by Amount
    23.2%
    RA Capital LLC.

  • macugen_rules by macugen_rules Jun 24, 2014 12:29 PM Flag

    Let me ask you this, are shorts still holding their Breath in VRTX this morning?LOL. Turning from Pale to Purple by now. That said the smart shorts can always scalp by shorting any stock. But there are always the stubborn ones who think by averaging up on their shorts would bring them profits such as those in Vertex this morning. They won't post much as Margin Calls are up the sore behind. You short Biotech stocks, your gains are minimum but your losses are exponential. Talking about averaging up on shorts, Mr. Sidelurker bet the farm shorting 23k of ACHN @ 6.89!LMAO.

    Sentiment: Hold

  • macugen_rules by macugen_rules Jun 24, 2014 11:43 AM Flag

    Dr. Deshpande is more upbeat and concise during his presentation. I can tell he has been working on his speech lately. Easier to understand and gets his point across. I was pounding the table for a while when touching on the subject of SOF+3102, the statement was ; results will be released in October (WTF?). But towards the end, he corrected himself and restated Results will be towards the end of August......What a Relief!

    Sentiment: Hold

  • macugen_rules by macugen_rules Jun 24, 2014 9:50 AM Flag

    Are you guys puking this morning in Vertex?

  • In Viral Load Reduction ( 4 weeks into treatment ) would set this stock in another upward movement. Very Achievable. Remember these patients are non-cirrhotic, non IL28B CT or TT type.

    Sentiment: Hold

  • Reply to

    Summer is Here

    by macugen_rules Jun 23, 2014 12:09 PM
    macugen_rules macugen_rules Jun 23, 2014 12:44 PM Flag

    I have No clue whatsoever. Only thing came to mind was Funds Repositioning Options and stocks during the last hour of trading. Last Friday wasn't simply another Expiration Day but it fell into Double or Triple Witching Day. Thus you see some ridiculous amount of transactions happened not only in ACHN but others as well.
    ...And I don't Care either!LOL.

    Sentiment: Hold

  • Reply to

    Summer is Here

    by macugen_rules Jun 23, 2014 12:09 PM
    macugen_rules macugen_rules Jun 23, 2014 12:34 PM Flag

    As far as SVR12 for the 12 Patients Arm, they will have to wait until EOT then another 4 to 6 six to collect Data which shall put the released date in late August or early September.

    Sentiment: Hold

  • Reply to

    Summer is Here

    by macugen_rules Jun 23, 2014 12:09 PM
    macugen_rules macugen_rules Jun 23, 2014 12:25 PM Flag

    Enrollment and trial started in April 30 of 2014.
    ' Achillion is conducting a Phase 2, open-label, randomized, partial-crossover study to evaluate the efficacy, safety, and tolerability of eight weeks or six weeks of ACH-3102 and sofosbuvir in treatment-naïve genotype 1 HCV-infected patients. The primary objective for the study is determination of sustained viral response 12 weeks (SVR12) after the completion of therapy. Twelve patients will be enrolled and receive eight weeks of treatment consisting of 50 mg of ACH-3102 and 400 mg of sofosbuvir administered once daily. The trial protocol also allows for the enrollment of additional HCV-infected patients who may be eligible to receive six weeks of treatment consisting of 50 mg of ACH-3102 and 400 mg of sofosbuvir administered once daily. Preliminary results from the eight-week treatment duration cohort are anticipated during the summer of 2014. This study is being conducted outside the United States.'
    So the Preliminary of the 6-week Cohort ie SVR4 could be released any day now. There are two Arms 12 for 8-week duration and another 8 patients for 6 weeks.

  • macugen_rules by macugen_rules Jun 23, 2014 12:09 PM Flag

    SVR4 data could be released any day now.

    Sentiment: Hold

VRTX
97.82-0.28(-0.29%)Jul 10 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.